Cardiovascular outcomes in breast cancer survivors: a systematic review and meta-analysis

Galimzhanov, Akhmetzhan; Mamas, MA; Tenekecioglu, Erhan; Tun, Han Naung; Alasnag, Mirvat; Ky, Bonnie; Lyon, Alexander R.; Panagioti, Maria; Evangelos Kontopantelis,; Abdel-Qadir, Husam

doi:10.6084/m9.figshare.23912031.v3

1/1

2 files

Cardiovascular outcomes in breast cancer survivors: a systematic review and meta-analysis

Version 3 2023-09-18, 18:03

Version 2 2023-09-18, 18:00

Version 1 2023-08-09, 13:18

journal contribution

posted on 2023-09-18, 18:03 authored by Akhmetzhan GalimzhanovAkhmetzhan Galimzhanov, MA Mamas, Erhan Tenekecioglu, Han Naung Tun, Mirvat Alasnag, Bonnie Ky, Alexander R. Lyon, Maria Panagioti, Evangelos Kontopantelis, Husam Abdel-Qadir

Aims

It is unclear whether the future risk of cardiovascular events in breast cancer (BC) survivors is greater than in the general population. This meta-analysis quantifies the risk of cardiovascular disease development in BC patients, compared to the risk in a general matched cancer-free population, and reports the incidence of cardiovascular events in patients with BC.

Methods and results

We searched PubMed, Scopus, and Web of Science databases (up to 23 March 2022) for observational studies and post hoc analyses of randomized controlled trials. Cardiovascular death, heart failure (HF), atrial fibrillation (AF), coronary artery disease (CAD), myocardial infarction (MI), and stroke were the individual endpoints for our meta-analysis. We pooled incidence rates (IRs) and risk in hazard ratios (HRs), using random-effects meta-analyses. Heterogeneity was reported through the I² statistic, and publication bias was examined using funnel plots and Egger’s test in the meta-analysis of risk. One hundred and forty-two studies were identified in total, 26 (836 301 patients) relevant to the relative risk and 116 (2 111 882 patients) relevant to IRs. Compared to matched cancer-free controls, BC patients had higher risk for cardiovascular death within 5 years of cancer diagnosis [HR = 1.09; 95% confidence interval (CI): 1.07, 1.11], HF within 10 years (HR = 1.21; 95% CI: 1.1, 1.33), and AF within 3 years (HR = 1.13; 95% CI: 1.05, 1.21). The pooled IR for cardiovascular death was 1.73 (95% CI 1.18, 2.53), 4.44 (95% CI 3.33, 5.92) for HF, 4.29 (95% CI 3.09, 5.94) for CAD, 1.98 (95% CI 1.24, 3.16) for MI, 4.33 (95% CI 2.97, 6.30) for stroke of any type, and 2.64 (95% CI 2.97, 6.30) for ischaemic stroke.

Conclusion

Breast cancer exposure was associated with the increased risk for cardiovascular death, HF, and AF. The pooled incidence for cardiovascular endpoints varied depending on population characteristics and endpoint studied.

Registration

CRD42022298741.